WAP
VKTX icon

Wealthcare Advisory Partners’s Viking Therapeutics VKTX Stock Holding History

Wealthcare Advisory Partners’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-107
Closed – – 1309
2018
Q2 		$0 Hold
107
– – ﹤0.01% 1319
2018
Q1 		$0 Buy
+107
New +$592 ﹤0.01% 1255

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Wealthcare Advisory Partners's VKTX Position: Q3 2018 in Review

Wealthcare Advisory Partners sold out of Viking Therapeutics (VKTX) in Q3 2018, closing a stake of 107 shares.

Wealthcare Advisory Partners first reported a position in VKTX in Q1 2018 and held it in 2 quarters. The position peaked at $0 in Q2 2018. 148 funds tracked by Wall St. Rank hold VKTX as of Q3 2018.

  • Wealthcare Advisory Partners reported no remaining Viking Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Wealthcare Advisory Partners sold 107 Viking Therapeutics shares in Q3 2018.
  • Wealthcare Advisory Partners first reported a position in Viking Therapeutics in Q1 2018 and held it in 2 quarters.
  • Wealthcare Advisory Partners's Viking Therapeutics position peaked at $0 in Q2 2018.
  • 148 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2018.

Based on Wealthcare Advisory Partners's 13F filing for Q3 2018, filed 14 Nov 2018.